Breaking News Instant updates and real-time market news.

2022-07-07 06:52:23 COLD Americold Realty Trust $30.99 / -0.58 (-1.84%) 06:52 07/07/22 07/07 06:52 07/07/22 06:52	Americold Realty Trust price target raised to $33 from $29 at Baird Baird analyst David Rodgers raised the firm's price target on Americold Realty Trust to $33 from $29 and keeps an Outperform rating on the shares. The analyst raised his 2022/2023 AFFO estimates and increased his fair value outlook and while he thinks a full recovery could take several years, his prior outlook now appears conservative.	04 Aug

2022-07-07 06:52:23

COLD

Americold Realty Trust

$30.99 / -0.58 (-1.84%)

06:52

07/07/22

07/07

06:52

07/07/22

06:52

Americold Realty Trust price target raised to $33 from $29 at Baird

Baird analyst David Rodgers raised the firm's price target on Americold Realty Trust to $33 from $29 and keeps an Outperform rating on the shares. The analyst raised his 2022/2023 AFFO estimates and increased his fair value outlook and while he thinks a full recovery could take several years, his prior outlook now appears conservative.

04
Aug

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Karuna Therapeutics price target raised to $261 from $160 at BofA » 06:25 08/09/22 08/09 06:25 08/09/22 06:25 KRTX Karuna Therapeutics $241.52 / +101.41 (+72.38%) BofA analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KRTX Karuna Therapeutics $241.52 / +101.41 (+72.38%) 08/08/22 Zai Lab partner Karuna announces results from Phase 3 EMERGENT-2 trial 08/08/22 Karuna Therapeutics says Phase 3 EMERGENT-2 trial met primary endpoint KRTX Karuna Therapeutics $241.52 / +101.41 (+72.38%) 08/08/22 Stifel Cerevel Therapeutics price target raised to $54 from $50 at Stifel 08/08/22 Stifel Karuna Therapeutics price target raised to $260 from $185 at Stifel 08/08/22 JMP Securities Karuna Therapeutics price target raised to $315 from $190 at JMP Securities 08/08/22 Citi Karuna Therapeutics price target raised to $280 from $162 at Citi KRTX Karuna Therapeutics $241.52 / +101.41 (+72.38%) 08/08/22 Karuna Therapeutics reports Q2 EPS ($2.17), consensus ($2.09) 05/05/22 Karuna Therapeutics reports Q1 EPS ($1.95), consensus ($2.11) 02/24/22 Karuna Therapeutics reports Q4 EPS (94c), consensus ($1.73) 10 Aug 10 Nov KRTX Karuna Therapeutics $241.52 / +101.41 (+72.38%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers 07/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/15/22 2022 Biotech Summer Summit
Recommendations	Aurinia Pharmaceuticals price target lowered to $26 from $30 at H.C. Wainwright » 06:24 08/09/22 08/09 06:24 08/09/22 06:24 AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) 07/26/22 Aurinia says USPTO to institute trial on Inter Partes review of Lupkynis patent 07/22/22 Aurinia Pharmaceuticals announces positive CHMP opinion for LUPKYNIS 07/14/22 Aurinia Pharmaceuticals names Scott Habig chief commercial officer 06/03/22 Aurinia Pharmaceuticals presents data from Lupkynis trial AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) 05/05/22 Cantor Fitzgerald Aurinia Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald 05/04/22 H.C. Wainwright Aurinia Pharmaceuticals price target lowered to $30 from $33 at H.C. Wainwright 04/28/22 RBC Capital Aurinia Pharmaceuticals price target lowered to $22 from $27 at RBC Capital 03/01/22 RBC Capital Aurinia Pharmaceuticals price target lowered to $27 from $31 at RBC Capital AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) 08/04/22 Aurinia Pharmaceuticals reports Q2 EPS (25c), consensus (22c) 05/10/22 Aurinia Pharmaceuticals reports Q1 EPS (27c), consensus (27c) 02/28/22 Aurinia Pharmaceuticals sees 2022 net revenue $115M-$135M 02/28/22 Aurinia Pharmaceuticals reports Q4 EPS (25c) vs. (6c) last year AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) 07/01/22 Aurinia Pharmaceuticals M&A rumor discussed by Betaville AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/28/22 What You Missed On Wall Street On Monday AUPH Aurinia Pharmaceuticals $8.28 / -0.075 (-0.90%) 07/27/22 Aurinia Pharmaceuticals call volume above normal and directionally bullish 07/01/22 Aurinia Pharmaceuticals call volume above normal and directionally bullish 06/22/22 Aurinia Pharmaceuticals call volume above normal and directionally bullish 06/08/22 Aurinia Pharmaceuticals call volume above normal and directionally bullish
Recommendations	Pliant Therapeutics price target raised to $53 from $45 at H.C. Wainwright » 06:24 08/09/22 08/09 06:24 08/09/22 06:24 PLRX Pliant Therapeutics $18.95 / +0.04 (+0.21%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options PLRX Pliant Therapeutics $18.95 / +0.04 (+0.21%) 07/21/22 Pliant receives FDA Fast Track designation for PLN-74809 for treating PSC 07/11/22 Pliant Therapeutics trading resumes 07/11/22 Pliant Therapeutics trading halted, volatility trading pause 07/10/22 Pliant announces safety, efficacy data from Phase 2a INTEGRIS-IPF trial PLRX Pliant Therapeutics $18.95 / +0.04 (+0.21%) 07/26/22 Cantor Fitzgerald Pliant Therapeutics price target raised to $40 from $36 at Cantor Fitzgerald 07/20/22 SVB Securities Pliant Therapeutics initiated with an Outperform at SVB Securities 07/11/22 Piper Sandler Pliant Therapeutics price target raised to $40 from $27 at Piper Sandler 07/11/22 Cantor Fitzgerald Pliant Therapeutics price target raised to $36 from $28 at Cantor Fitzgerald PLRX Pliant Therapeutics $18.95 / +0.04 (+0.21%) 08/08/22 Pliant Therapeutics reports Q2 EPS (82c), consensus (81c) 05/09/22 Pliant Therapeutics reports Q1 EPS (78c), consensus (75c) 02/28/22 Pliant Therapeutics reports Q4 EPS (68c), consensus (76c) 13 Jul PLRX Pliant Therapeutics $18.95 / +0.04 (+0.21%) 07/11/22 What You Missed On Wall Street On Monday 07/11/22 What You Missed On Wall Street This Morning PLRX Pliant Therapeutics $18.95 / +0.04 (+0.21%) 07/12/22 Unusually active option classes on open July 12th
Syndicate	PennantPark Floating Rate 4M share Spot Secondary priced at $12.40 » 06:23 08/09/22 08/09 06:23 08/09/22 06:23 PFLT PennantPark Floating Rate $13.21 / +0.3 (+2.32%) The deal range was… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate PFLT PennantPark Floating Rate $13.21 / +0.3 (+2.32%) 05/06/22 PennantPark Floating Rate appoints Jose Briones to board of directors 03/14/22 PennantPark Floating Rate increases commitment to joint venture PFLT PennantPark Floating Rate $13.21 / +0.3 (+2.32%) 08/09/21 Ladenburg PennantPark Floating Rate downgraded to Neutral at Ladenburg 08/09/21 Ladenburg PennantPark Floating Rate downgraded to Neutral from Buy at Ladenburg PFLT PennantPark Floating Rate $13.21 / +0.3 (+2.32%) 05/04/22 PennantPark Floating Rate reports Q2 EPS 29c, consensus 28c 09 Aug
Recommendations	Acadia Pharmaceuticals price target raised to $25 from $20 at H.C. Wainwright » 06:23 08/09/22 08/09 06:23 08/09/22 06:23 ACAD Acadia Pharmaceuticals $16.65 / +0.225 (+1.37%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ACAD Acadia Pharmaceuticals $16.65 / +0.225 (+1.37%) 08/05/22 Acadia Pharmaceuticals receives CRL from FDA regarding Nuplazid sNDA 07/18/22 Acadia Pharmaceuticals submits NDA to FDA for Rett Syndrome treatment 06/21/22 Acadia Pharmaceuticals down 30% after FDA AdCom vote against Nuplazid 06/18/22 Acadia 'disappointed' with PDAC vote of 9 to 3 against Nuplazid in ADP ACAD Acadia Pharmaceuticals $16.65 / +0.225 (+1.37%) 05:40 Today Citi Acadia Pharmaceuticals price target raised to $17 from $15 at Citi 08/08/22 Cowen Acadia Pharmaceuticals price target lowered to $21 from $32 at Cowen 08/05/22 Citi Acadia Pharmaceuticals downgraded to Neutral from Buy at Citi 06/22/22 Canaccord Acadia Pharmaceuticals price target lowered to $20 from $31 at Canaccord ACAD Acadia Pharmaceuticals $16.65 / +0.225 (+1.37%) 08/08/22 Acadia Pharmaceuticals narrows FY22 revenue view to $510M-$540M from $510M-$560M 08/08/22 Acadia Pharmaceuticals reports Q2 EPS (21c), consensus (25c) 05/04/22 Acadia Pharmaceuticals backs FY22 revenue view of $510M-$560M, consensus $540.7M 05/04/22 Acadia Pharmaceuticals reports Q1 EPS (70c), consensus (60c) ACAD Acadia Pharmaceuticals $16.65 / +0.225 (+1.37%) 06/21/22 What You Missed On Wall Street On Tuesday 06/21/22 What You Missed On Wall Street This Morning 06/21/22 Fly Intel: Pre-market Movers 06/16/22 What You Missed On Wall Street On Thursday ACAD Acadia Pharmaceuticals $16.65 / +0.225 (+1.37%) 07/15/22 Acadia call volume above normal and directionally bullish 07/12/22 Acadia call volume above normal and directionally bullish 06/15/22 Unusually active option classes on open June 15th 05/04/22 Acadia options imply 19.6% move in share price post-earnings
Recommendations	PubMatic price target lowered to $34 from $40 at JMP Securities » 06:23 08/09/22 08/09 06:23 08/09/22 06:23 PUBM PubMatic $17.81 / +0.365 (+2.09%) JMP Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PUBM PubMatic $17.81 / +0.365 (+2.09%) 06/21/22 PubMatic to join broad-market Russell 3000 and the small-cap 2000 indexes 06/16/22 PubMatic achieves 100% renewable energy across global data centers 06/07/22 PubMatic names Zendesk CFO Glaser and JFrog CFO Shulman to board 02/24/22 PubMatic selected by GroupM to support supply chain PUBM PubMatic $17.81 / +0.365 (+2.09%) 08/04/22 Jefferies PubMatic price target lowered to $20 from $23 at Jefferies 08/01/22 KeyBanc PubMatic downgraded to Sector Weight from Overweight at KeyBanc 07/27/22 KeyBanc Google's cookie phase-out delay not surprising, says KeyBanc 07/27/22 RBC Capital Google cookie phase-out delay adds another year of uncertainty, says RBC Capital PUBM PubMatic $17.81 / +0.365 (+2.09%) 08/08/22 PubMatic cuts FY22 revenue view to $277M-$281M from $282M-$286M 08/08/22 PubMatic sees Q3 revenue $66M-$68M, consensus $69.51M 08/08/22 PubMatic reports Q2 EPS 23c vs. 18c last year 05/09/22 PubMatic backs FY22 revenue view $282M-$286M, consensus $284.22M PUBM PubMatic $17.81 / +0.365 (+2.09%) 06/15/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/28/22 Fly Intel: After-Hours Movers 08/16/22 PubMatic PUBM PubMatic $17.81 / +0.365 (+2.09%) 02/25/22 Largest borrow rate increases among liquid names
Hot Stocks	Village Farms announces Leli Holland been granted tenth cannabis license » 06:23 08/09/22 08/09 06:23 08/09/22 06:23 VFF Village Farms $3.13 / -0.06 (-1.88%) Village Farms announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VFF Village Farms $3.13 / -0.06 (-1.88%) 07/19/22 Pure Sunfarms launches The Original Fraser Valley Weed Co. 05/03/22 Village Farms' Pure Sunfarms, NOYA bring Cookies sun-grown flower to Ontario 04/20/22 Pure Sunfarms launches Pure Sunfarms FLOWERHOOD 03/09/22 Village Farms' Pure Sunfarms receives EU GMP certification for production unit VFF Village Farms $3.13 / -0.06 (-1.88%) 05/11/22 Craig-Hallum Village Farms price target lowered to $5 from $15 at Craig-Hallum 05/11/22 Raymond James Village Farms downgraded to Outperform from Strong Buy at Raymond James 05/10/22 Alliance Global Partners Village Farms price target lowered to $10 from $17 at Alliance Global Partners 03/03/22 Stifel Village Farms downgraded to Hold from Buy at Stifel VFF Village Farms $3.13 / -0.06 (-1.88%) 06:21 Today Village Farms reports Q2 EPS (41c) vs. (13c) last year 05/10/22 Village Farms reports Q1 EPS (7c), consensus (1c) 03/01/22 Village Farms reports Q4 EPS 3c, consensus 2c 08:30 Today Village Farms - VFF
Recommendations	uniQure selloff brings attractive entry point, says H.C. Wainwright » 06:21 08/09/22 08/09 06:21 08/09/22 06:21 QURE uniQure $18.60 / -6.92 (-27.12%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events QURE uniQure $18.60 / -6.92 (-27.12%) 06/23/22 uniQure provides update on low-dose cohort in Phase I/II trial of AMT-130 06/22/22 uniQure announces grant equity awards to 32 new employees 05/24/22 uniQure announces FDA accepts priority review BLA for etranacogene dezaparvovec 05/11/22 uniQure announces inducement grants under Nasdaq listing rule 5635(c)(4) QURE uniQure $18.60 / -6.92 (-27.12%) 08/08/22 Chardan uniQure price target lowered to $60 from $65 at Chardan 08/08/22 Truist uniQure's high-dose HD data still on track for 1H23, says Truist 05/05/22 Stifel uniQure price target lowered to $37 from $66 at Stifel 04/13/22 Truist uniQure price target lowered to $51 from $90 at Truist QURE uniQure $18.60 / -6.92 (-27.12%) 08/08/22 uniQure reports Q2 EPS (84c) vs $8.51 last year 05/02/22 uniQure reports Q1 EPS ($1.00), consensus (93c) 02/25/22 uniQure reports 2021 EPS $7.04, consensus $6.20 QURE uniQure $18.60 / -6.92 (-27.12%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 06/23/22 What You Missed On Wall Street On Thursday 06/23/22 What You Missed On Wall Street This Morning 10/03/22 6th Annual Genetic Medicines Conference
Earnings	Village Farms reports Q2 EPS (41c) vs. (13c) last year » 06:21 08/09/22 08/09 06:21 08/09/22 06:21 VFF Village Farms $3.13 / -0.06 (-1.88%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VFF Village Farms $3.13 / -0.06 (-1.88%) 07/19/22 Pure Sunfarms launches The Original Fraser Valley Weed Co. 05/03/22 Village Farms' Pure Sunfarms, NOYA bring Cookies sun-grown flower to Ontario 04/20/22 Pure Sunfarms launches Pure Sunfarms FLOWERHOOD 03/09/22 Village Farms' Pure Sunfarms receives EU GMP certification for production unit VFF Village Farms $3.13 / -0.06 (-1.88%) 05/11/22 Craig-Hallum Village Farms price target lowered to $5 from $15 at Craig-Hallum 05/11/22 Raymond James Village Farms downgraded to Outperform from Strong Buy at Raymond James 05/10/22 Alliance Global Partners Village Farms price target lowered to $10 from $17 at Alliance Global Partners 03/03/22 Stifel Village Farms downgraded to Hold from Buy at Stifel VFF Village Farms $3.13 / -0.06 (-1.88%) 05/10/22 Village Farms reports Q1 EPS (7c), consensus (1c) 03/01/22 Village Farms reports Q4 EPS 3c, consensus 2c 08:30 Today Village Farms - VFF
General news	European stock markets are narrowly mixed, » 06:20 08/09/22 08/09 06:20 08/09/22 06:20 $ECON Economic Data / + European stock markets… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly $ECON Economic Data / + 06/22/22 President Biden calls on Congress to suspend federal gas tax 05/19/22 Could crypto crash be good for U.S. economy? Probably. 05/12/22 Miller calls out Taylor Morrison, GM as names that may work in this environment 04/21/22 Powell says 50 basis point hike on table for May meeting $ECON Economic Data / + $ECON Economic Data / + 06/14/22 Ackman says 100 point hike tomorrow 'would be better' than 75 02/11/22 Gundlach sees five interest rate raises in 2022 $ECON Economic Data / + 07/26/22 Ackman says biggest risk to economy is inflation, not higher rates 06/17/22 White House, Congress in talks over bill to fight inflation, Bloomberg says 06/13/22 Fed more likely to consider 0.75 point hike given recent data, WSJ says 05/10/22 Tepper says covered Nasdaq short, CNBC reports $ECON Economic Data / + 07/27/22 What You Missed On Wall Street On Wednesday 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed On Wall Street On Wednesday

General news	U.S. productivity preview » 06:20 08/09/22 08/09 06:20 08/09/22 06:20 $ECON Economic Data / + U.S. productivity… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly $ECON Economic Data / + 06/22/22 President Biden calls on Congress to suspend federal gas tax 05/19/22 Could crypto crash be good for U.S. economy? Probably. 05/12/22 Miller calls out Taylor Morrison, GM as names that may work in this environment 04/21/22 Powell says 50 basis point hike on table for May meeting $ECON Economic Data / + $ECON Economic Data / + 06/14/22 Ackman says 100 point hike tomorrow 'would be better' than 75 02/11/22 Gundlach sees five interest rate raises in 2022 $ECON Economic Data / + 07/26/22 Ackman says biggest risk to economy is inflation, not higher rates 06/17/22 White House, Congress in talks over bill to fight inflation, Bloomberg says 06/13/22 Fed more likely to consider 0.75 point hike given recent data, WSJ says 05/10/22 Tepper says covered Nasdaq short, CNBC reports $ECON Economic Data / + 07/27/22 What You Missed On Wall Street On Wednesday 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed On Wall Street On Wednesday
Upgrade	Myovant Sciences upgraded to Outperform from Market Perform at SVB Securities » 06:19 08/09/22 08/09 06:19 08/09/22 06:19 MYOV Myovant Sciences / + SVB Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly MYOV Myovant Sciences / + 08/07/22 Myovant Sciences, Pfizer receive FDA approval of MYFEMBREE 06/17/22 Pfizer, Myovant Sciences announce results of Phase 3 SPIRIT 1, SPIRIT 2 studies 06/07/22 Better Therapeutics appoints Karbe as Chief Executive Officer 06/02/22 Pfizer, Myovant Sciences announce FDA approval of sNDA for MYFEMBREE MYOV Myovant Sciences / + 06:11 Today SVB Securities Myovant Sciences upgraded to Outperform from Market Perform at SVB Securities 04/13/22 Baird Myovant Sciences price target lowered to $20 from $30 at Baird 09/09/21 SVB Leerink SVB Leerink starts Myovant at Market Perform 09/09/21 SVB Leerink Myovant Sciences initiated with a Market Perform at SVB Leerink MYOV Myovant Sciences / + 05/10/22 Myovant Sciences reports Q4 EPS (63c), consensus (57c) MYOV Myovant Sciences / + 04/12/22 What You Missed On Wall Street On Tuesday 04/12/22 What You Missed On Wall Street This Morning 04/12/22 Fly Intel: Pre-market Movers
Recommendations	Precigen price target lowered to $6 from $10 at H.C. Wainwright » 06:19 08/09/22 08/09 06:19 08/09/22 06:19 PGEN Precigen $2.07 / -0.01 (-0.48%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PGEN Precigen $2.07 / -0.01 (-0.48%) 08/08/22 Precigen expectsTrans Ova Genetics sale to close in Q3 07/05/22 Precigen enters agreement to divest non-healthcare subsidiary Trans Ova to URUS 04/04/22 Precigen says FDA grants Fast Track designation for PRGN-3006 UltraCAR-T PGEN Precigen $2.07 / -0.01 (-0.48%) 07/05/22 Stifel Precigen subsidiary sale relieves convertible debt overhang, says Stifel PGEN Precigen $2.07 / -0.01 (-0.48%) 08/08/22 Precigen reports Q2 EPS (13c), consensus (16c) 05/09/22 Precigen reports Q1 EPS (10c), consensus (13c) 03/01/22 Precigen reports Q4 EPS (13c), consensus (14c)
Recommendations	SpringsWorks Therapeutics price target lowered to $94 from $95 at H.C. Wainwright » 06:18 08/09/22 08/09 06:18 08/09/22 06:18 SWTX SpringsWorks Therapeutics $39.68 / +2.825 (+7.67%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SWTX SpringsWorks Therapeutics $39.68 / +2.825 (+7.67%) 05/26/22 SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO 05/24/22 SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial 04/19/22 SpringsWorks announces agreeement with Regeneron for nirogacestat SWTX SpringsWorks Therapeutics $39.68 / +2.825 (+7.67%) 06/06/22 H.C. Wainwright SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright 06/06/22 H.C. Wainwright Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 05/27/22 Wedbush SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush 05/24/22 Goldman Sachs SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs SWTX SpringsWorks Therapeutics $39.68 / +2.825 (+7.67%) 08/04/22 SpringsWorks Therapeutics reports Q2 EPS ($1.41), consensus ($1.20) 05/05/22 SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02) 02/24/22 SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c) SWTX SpringsWorks Therapeutics $39.68 / +2.825 (+7.67%) 06/24/22 Sell these stocks now, proven algorithm says 06/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/26/22 Fly Intel: After-Hours Movers 05/24/22 What You Missed On Wall Street On Tuesday 09/10/22 ESMO Congress 2022
Hot Stocks	Huntsman to sell Textile Effects division to Archroma for $718M » 06:18 08/09/22 08/09 06:18 08/09/22 06:18 HUN Huntsman $29.26 / +0.34 (+1.18%) Huntsman announced it has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly HUN Huntsman $29.26 / +0.34 (+1.18%) 05/13/22 Starboard takes stake in Humana, exits System1 05/02/22 Huntsman awarded $93.8M by New Orleans Jury in case against Praxair/Linde 04/19/22 Huntsman comments on pending discrimination lawsuit 03/28/22 Huntsman increases share repurchase authorization to $2B from $1B HUN Huntsman $29.26 / +0.34 (+1.18%) 08/04/22 Citi Huntsman price target lowered to $34 from $35 at Citi 08/03/22 Deutsche Bank Huntsman price target lowered to $35 from $40 at Deutsche Bank 07/25/22 UBS Huntsman downgraded to Neutral from Buy at UBS 06/22/22 Wells Fargo Huntsman price target lowered to $35 from $42 at Wells Fargo HUN Huntsman $29.26 / +0.34 (+1.18%) 08/02/22 Huntsman reports Q2 adjusted EPS $1.28, consensus $1.15 04/28/22 Huntsman reports Q1 adjusted EPS $1.19, consensus $1.03 02/15/22 Huntsman reports Q4 EPS 95c, consensus 91c HUN Huntsman $29.26 / +0.34 (+1.18%) 06/28/22 Huntsman in discussions to sell textiles business to SK Capital, Bloomberg says 03/25/22 Starboard fails to gain support to replace four on Huntsman board, Reuters says 03/25/22 Huntsman falls after Bloomberg says Starboard loses board vote HUN Huntsman $29.26 / +0.34 (+1.18%) 03/25/22 What You Missed On Wall Street On Friday 03/25/22 What You Missed On Wall Street This Morning
Recommendations	Relay Therapeutics price target lowered to $46 from $47 at H.C. Wainwright » 06:18 08/09/22 08/09 06:18 08/09/22 06:18 RLAY Relay Therapeutics $19.85 / +0.15 (+0.76%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings Syndicate RLAY Relay Therapeutics $19.85 / +0.15 (+0.76%) 06/06/22 Jefferies Relay Therapeutics initiated with an Underperform at Jefferies 05/10/22 H.C. Wainwright Relay Therapeutics price target lowered to $47 from $54 at H.C. Wainwright 05/09/22 JMP Securities Relay Therapeutics price target lowered to $35 from $50 at JMP Securities 02/01/22 Berenberg Relay Therapeutics initiated with a Buy at Berenberg RLAY Relay Therapeutics $19.85 / +0.15 (+0.76%) 08/04/22 Relay Therapeutics reports Q2 EPS (71c) vs. ($2.10) last year 05/05/22 Relay Therapeutics reports Q1 EPS (57c), consensus (62c) 02/24/22 Relay Therapeutics reports Q4 EPS ($3.82), consensus (58c) 13 Oct
Upgrade	Inspirato upgraded to Overweight from Neutral at Cantor Fitzgerald » 06:17 08/09/22 08/09 06:17 08/09/22 06:17 ISPO Inspirato $4.93 / -0.11 (-2.18%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ISPO Inspirato $4.93 / -0.11 (-2.18%) 06/09/22 Inspirato announces Inspirato Select subscription 04/21/22 Tang Capital reports 5.0% passive stake in Inspirato 04/18/22 Inspirato announces 11 new luxury residences at 71 Wentworth 04/11/22 Inspirato announces 2023 luxury cruise program ISPO Inspirato $4.93 / -0.11 (-2.18%) 08/08/22 Piper Sandler Inspirato price target lowered to $7 from $9 at Piper Sandler 07/22/22 Cantor Fitzgerald Inspirato assumed with a Neutral at Cantor Fitzgerald 06/28/22 Stifel Inspirato price target lowered to $6 from $7 at Stifel 06/14/22 Oppenheimer Inspirato initiated with a Perform at Oppenheimer ISPO Inspirato $4.93 / -0.11 (-2.18%) 08/08/22 Inspirato reports Q2 EPS (6c) vs (1c) last year 05/11/22 Inspirato sees FY22 revenue $350M-$360M, consensus $354.13M 05/11/22 Inspirato reports Q1 EPS (26c), consensus (47c) ISPO Inspirato $4.93 / -0.11 (-2.18%) 06/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/11/22 Fly Intel: After-Hours Movers 04/21/22 Fly Intel: After-Hours Movers ISPO Inspirato $4.93 / -0.11 (-2.18%) 07/11/22 Largest borrow rate increases among liquid names 07/07/22 Largest borrow rate increases among liquid names 05/11/22 Inspirato options imply 7.9% move in share price post-earnings 05/11/22 Largest borrow rate increases among liquid names
Initiation	Finch Therapeutics initiated with a Buy at H.C. Wainwright » 06:17 08/09/22 08/09 06:17 08/09/22 06:17 FNCH Finch Therapeutics $2.47 / +0.22 (+9.78%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options FNCH Finch Therapeutics $2.47 / +0.22 (+9.78%) 05/16/22 Finch Therapeutics expects cash to fund operations into 2Q24 04/28/22 Finch Therapeutics announces removal of FDA clinical hold on CP101 IND 04/19/22 Finch Therapeutics to reduce workforce by 20% to focus on key programs 03/17/22 Finch Therapeutics Group Inc trading resumes FNCH Finch Therapeutics $2.47 / +0.22 (+9.78%) 04/04/22 Jefferies Finch Therapeutics price target lowered to $17 from $29 at Jefferies FNCH Finch Therapeutics $2.47 / +0.22 (+9.78%) 05/16/22 Finch Therapeutics reports Q1 EPS (52c) vs. ($1.00) last year FNCH Finch Therapeutics $2.47 / +0.22 (+9.78%) 04/29/22 Fly Intel: Pre-market Movers FNCH Finch Therapeutics $2.47 / +0.22 (+9.78%) 03/23/22 Nine new option listings on March 23rd
Recommendations	Tyson Foods price target lowered to $90 from $99 at BMO Capital » 06:16 08/09/22 08/09 06:16 08/09/22 06:16 TSN Tyson Foods $80.10 / -7.395 (-8.45%) BMO Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TSN Tyson Foods $80.10 / -7.395 (-8.45%) 08/08/22 Tyson Foods: Demand for chicken 'extremely strong' 08/08/22 Tyson: Prepared fods unit can't fulfill all orders due to supply constraints 08/08/22 Tyson Foods CEO says demand 'relatively steady' 08/08/22 Tyson Foods focused on overcoming supply chain challenges, says CEO TSN Tyson Foods $80.10 / -7.395 (-8.45%) 05:55 Today Barclays Tyson Foods price target lowered to $89 from $100 at Barclays 04:57 Today Piper Sandler Piper upgrades Tyson Foods to Neutral with risks priced in 08/08/22 Piper Sandler Tyson Foods upgraded to Neutral from Underweight at Piper Sandler 07/20/22 Cleveland Research Tyson Foods downgraded to Neutral from Buy at Cleveland Research TSN Tyson Foods $80.10 / -7.395 (-8.45%) 08/08/22 Tyson Foods sees 2022 revenue $52B-$54B, consensus $52.8B 08/08/22 Tyson Foods reports Q3 adjusted EPS $1.94 vs. $2.70 last year 07/06/22 Tyson Foods buys strategic stake in Tanmiah of Saudi Arabia 05/09/22 Tyson Foods raises FY22 revenue view to $52B-$54B from $49B-$51B TSN Tyson Foods $80.10 / -7.395 (-8.45%) 08/03/22 NY AG says Tyson ignoring subpoena for meat price investigation, Reuters says 07/11/22 Tyson Foods works to fix operations as it falls behind competitors, WSJ reports 02/15/22 Tyson Foods to ease mask rules at some processing plants, NY Times reports TSN Tyson Foods $80.10 / -7.395 (-8.45%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers 07/11/22 What You Missed On Wall Street On Monday TSN Tyson Foods $80.10 / -7.395 (-8.45%) 08/08/22 Unusually active option classes on open August 8th 03/14/22 Unusually active option classes on open March 14th 03/04/22 Tyson Foods put volume heavy and directionally bearish 03/02/22 Unusually active option classes on open March 2nd
Recommendations	Signify Health, CVS deal could be 'win-win,' says Deutsche Bank » 06:16 08/09/22 08/09 06:16 08/09/22 06:16 SGFY Signify Health $22.06 / +2.195 (+11.05%) , CVS CVS Health $102.00 / -0.34 (-0.33%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options SGFY CVS SGFY Signify Health $22.06 / +2.195 (+11.05%) 08/08/22 Signify Health rises 14.5% 08/08/22 Signify Health rises 15.9% 08/07/22 Fly Intel: Top five weekend stock stories 08/03/22 Signify Health sees FY HCS revenue $800M-$810M CVS CVS Health $102.00 / -0.34 (-0.33%) 08/07/22 Fly Intel: Top five weekend stock stories 08/04/22 CDW appoints Carolyn Wiesenhahn as CPO 08/03/22 CVS Health says liquidity, cash position 'remain excellent' 08/03/22 CVS Health says posted strong results across all business segments in Q2 SGFY CVS SGFY Signify Health $22.06 / +2.195 (+11.05%) 08/08/22 Cowen Signify Health price target raised to $24 from $14 at Cowen 08/08/22 BofA CVS deal for Signify would help with continued evolution, says BofA 08/04/22 Piper Sandler Signify Health price target raised to $34 from $32 at Piper Sandler 07/28/22 RBC Capital Signify Health initiated with a Sector Perform at RBC Capital CVS CVS Health $102.00 / -0.34 (-0.33%) 08/08/22 BofA CVS deal for Signify would help with continued evolution, says BofA 08/04/22 Evercore ISI CVS Health removed from 'TAP Outperform' list at Evercore ISI 08/04/22 Deutsche Bank CVS Health price target raised to $120 from $113 at Deutsche Bank 07/21/22 Stifel Logical to see Oak Street, Cano as 'in play' after 1Life deal, says Stifel SGFY CVS SGFY Signify Health $22.06 / +2.195 (+11.05%) 08/03/22 Signify Health reports Q2 EPS ($2.10), consensus 10c 05/04/22 Signify Health reaffirms FY22 revenue view $948M-$971M, consensus $961.01M 05/04/22 Signify Health reports Q1 EPS (6c), consensus 4c 03/02/22 Signify Health sees FY22 revenue $948M-$971M, consensus $928.21M CVS CVS Health $102.00 / -0.34 (-0.33%) 08/03/22 CVS Health raises FY22 revenue view to $307B-$312B from $305B-$310B 08/03/22 CVS Health raises 2022 adjusted EPS view $8.40-$8.60 from $8.20-$8.40 08/03/22 CVS Health reports Q2 adjusted EPS $2.40, consensus $2.17 08/02/22 Notable companies reporting before tomorrow's open SGFY CVS SGFY Signify Health $22.06 / +2.195 (+11.05%) 08/07/22 CVS planning to bid for Signify Health, WSJ reports 08/02/22 Signify Health working with bankers on potential sale, WSJ reports 08/02/22 Signify Health exploring options, including possible sale, WSJ says CVS CVS Health $102.00 / -0.34 (-0.33%) 08/07/22 CVS planning to bid for Signify Health, WSJ reports 07/05/22 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says 07/05/22 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says 06/27/22 CVS, Walmart rationing Plan B pills amid demand surge, WSJ reports SGFY CVS SGFY Signify Health $22.06 / +2.195 (+11.05%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers 08/03/22 Fly Intel: After-Hours Movers CVS CVS Health $102.00 / -0.34 (-0.33%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning CVS CVS CVS Health $102.00 / -0.34 (-0.33%) 08/03/22 Unusually active option classes on open August 3rd 07/14/22 CVS Health call volume above normal and directionally bullish 06/02/22 CVS Health put volume heavy and directionally bearish 05/04/22 Unusually active option classes on open May 4th

Hot Stocks	Louisiana-Pacific sees Q3 adjusted EBITDA $200M » 06:15 08/09/22 08/09 06:15 08/09/22 06:15 LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) Sees FY22 capital… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) 06/21/22 Pacific Woodtech to acquire LP Building's EWP business for $210M 05/03/22 Louisiana-Pacific sees Q2 adjusted EBITDA over $540M 03/04/22 Resolutet acquires Louisiana-Pacific's 50% stake in Resolute-Engineered Wood JV 02/22/22 Louisiana-Pacific sees FY22 CapEx $400M-$430M LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) 06/29/22 Truist Louisiana-Pacific initiated with a Hold at Truist 06/23/22 TD Securities Louisiana-Pacific price target lowered to $75 from $85 at TD Securities 06/23/22 BofA Louisiana-Pacific downgraded to Neutral at BofA on housing slowdown 06/23/22 BofA Louisiana-Pacific downgraded to Neutral from Buy at BofA LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) 06:15 Today Louisiana-Pacific reports Q2 adjusted EPS $4.19, consensus $4.40 05/03/22 Louisiana-Pacific reports Q1 adjusted EPS $5.08, consensus $4.62 02/22/22 Louisiana-Pacific sees Q1 adjusted EBITDA greater than $500M 02/22/22 Louisiana-Pacific reports Q4 adjusted EPS $2.24, consensus $2.02 11:00 Today Louisiana-Pacific - LPX
Earnings	Louisiana-Pacific reports Q2 adjusted EPS $4.19, consensus $4.40 » 06:15 08/09/22 08/09 06:15 08/09/22 06:15 LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) 06/21/22 Pacific Woodtech to acquire LP Building's EWP business for $210M 05/03/22 Louisiana-Pacific sees Q2 adjusted EBITDA over $540M 03/04/22 Resolutet acquires Louisiana-Pacific's 50% stake in Resolute-Engineered Wood JV 02/22/22 Louisiana-Pacific sees FY22 CapEx $400M-$430M LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) 06/29/22 Truist Louisiana-Pacific initiated with a Hold at Truist 06/23/22 TD Securities Louisiana-Pacific price target lowered to $75 from $85 at TD Securities 06/23/22 BofA Louisiana-Pacific downgraded to Neutral at BofA on housing slowdown 06/23/22 BofA Louisiana-Pacific downgraded to Neutral from Buy at BofA LPX Louisiana-Pacific $62.58 / +1.175 (+1.91%) 05/03/22 Louisiana-Pacific reports Q1 adjusted EPS $5.08, consensus $4.62 02/22/22 Louisiana-Pacific sees Q1 adjusted EBITDA greater than $500M 02/22/22 Louisiana-Pacific reports Q4 adjusted EPS $2.24, consensus $2.02 11:00 Today Louisiana-Pacific - LPX
Hot Stocks	Google back up after brief outage Monday night, says Downdetector » 06:14 08/09/22 08/09 06:14 08/09/22 06:14 GOOG Alphabet $118.17 / -0.11 (-0.09%) , GOOGL Alphabet $117.32 / -0.17 (-0.14%) Google services appear to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 08/08/22 Clover Health CEO Vivek Garipalli to switch roles, Andrew Toy to succeed 08/02/22 Mandiant to not provide guidance due to pending transaction with Google 08/02/22 Thryv and Google team to streamline communication for small businesses 07/31/22 Fly Intel: Top five weekend stock stories GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08/08/22 Clover Health CEO Vivek Garipalli to switch roles, Andrew Toy to succeed 08/02/22 Mandiant to not provide guidance due to pending transaction with Google 07/31/22 Fly Intel: Top five weekend stock stories 07/29/22 Google says Stadia game streaming service not shutting down GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 08/03/22 Tigress Financial Alphabet price target raised to $186 from $183 at Tigress Financial 07/27/22 Truist Chrome cookie phase-out delay positive for Criteo, says Truist 07/27/22 KeyBanc Google's cookie phase-out delay not surprising, says KeyBanc 07/27/22 RBC Capital Google cookie phase-out delay adds another year of uncertainty, says RBC Capital GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08/03/22 Tigress Financial Alphabet price target raised to $186 from $183 at Tigress Financial 07/27/22 Truist Chrome cookie phase-out delay positive for Criteo, says Truist 07/27/22 KeyBanc Google's cookie phase-out delay not surprising, says KeyBanc 07/27/22 RBC Capital Google cookie phase-out delay adds another year of uncertainty, says RBC Capital GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 07/26/22 Alphabet reports Q2 EPS $1.21, consensus $1.30 07/26/22 Notable companies reporting after market close 04/26/22 Alphabet reports Q1 EPS $24.62, consensus $25.96 04/26/22 Notable companies reporting after market close GOOGL Alphabet $117.32 / -0.17 (-0.14%) 07/26/22 Alphabet reports Q2 EPS $1.21, consensus $1.30 07/26/22 Notable companies reporting after market close 04/26/22 Alphabet reports Q1 EPS $24.62, consensus $25.96 04/26/22 Notable companies reporting after market close GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 08/08/22 Google files two more patent lawsuits against Sonos, Bloomberg Law reports 08/04/22 EU antitrust enforcers to investigate Google Play Store rules, Politico reports 08/02/22 Rumble allowed to proceed with antitrust suit against Google, Verge reports 08/01/22 Amazon hires senior congressional aide to fight antitrust bill, Bloomberg says GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08/08/22 Google files two more patent lawsuits against Sonos, Bloomberg Law reports 08/04/22 EU antitrust enforcers to investigate Google Play Store rules, Politico reports 08/02/22 Rumble allowed to proceed with antitrust suit against Google, Verge reports 08/01/22 Amazon hires senior congressional aide to fight antitrust bill, Bloomberg says GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/04/22 What You Missed On Wall Street This Morning 08/03/22 #SocialStocks: Five-day trial between Twitter and Elon Musk set for October 17 GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/04/22 What You Missed On Wall Street This Morning 08/03/22 #SocialStocks: Five-day trial between Twitter and Elon Musk set for October 17 GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 07/26/22 Alphabet options imply 6.1% move in share price post-earnings 07/25/22 Unusually active option classes on open July 25th 07/25/22 Alphabet put buyer realizes 47% same-day gains 07/22/22 Unusually active option classes on open July 22nd GOOGL Alphabet $117.32 / -0.17 (-0.14%) 07/27/22 Notable open interest changes for July 27th 07/26/22 Alphabet Class A options imply 6.1% move in share price post-earnings 07/25/22 Unusually active option classes on open July 25th 07/22/22 Unusually active option classes on open July 22nd
Earnings	Patria Investments reports Q2 EPS 20c, consensus 21c » 06:14 08/09/22 08/09 06:14 08/09/22 06:14 PAX Patria Investments $15.35 / +0.35 (+2.33%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings Events PAX Patria Investments $15.35 / +0.35 (+2.33%) 06/09/22 Patria Investments to acquire VBI Real Estate, terms not disclosed PAX Patria Investments $15.35 / +0.35 (+2.33%) 05/10/22 Patria Investments reports Q1 EPS 24c, consensus 18c 02/15/22 Patria Investments reports Q4 EPS 19c, consensus 19c 09:00 Today Patria Investments - PAX
Recommendations	Keysight Technologies price target raised to $190 from $176 at Deutsche Bank » 06:13 08/09/22 08/09 06:13 08/09/22 06:13 KEYS Keysight Technologies $166.33 / -0.99 (-0.59%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KEYS Keysight Technologies $166.33 / -0.99 (-0.59%) 08/03/22 Keysight, Nokia collaborate on public 800GE test 07/29/22 The Digital IF Interoperability Consortium announces seven new members 07/13/22 AI-LINK selects Keysight's 5G test tools for performance validation 06/22/22 Keysight selected by Azcom for verifying O-RAN equipment KEYS Keysight Technologies $166.33 / -0.99 (-0.59%) 07/14/22 JPMorgan Keysight Technologies price target lowered to $176 from $200 at JPMorgan 06/17/22 UBS Keysight Technologies price target lowered to $177 from $220 at UBS 06/01/22 Goldman Sachs Keysight Technologies price target lowered to $165 from $185 at Goldman Sachs 05/18/22 JPMorgan Keysight Technologies price target lowered to $200 from $230 at JPMorgan KEYS Keysight Technologies $166.33 / -0.99 (-0.59%) 05/17/22 Keysight Technologies sees FY22 EPS up 14%-15%, consensus $7.01 05/17/22 Keysight Technologies sees Q3 EPS $1.74-$1.80, consensus $1.75 05/17/22 Keysight Technologies reports Q2 EPS $1.83, consensus $1.67 02/17/22 Keysight Technologies sees Q2 adjusted EPS $1.63-$1.69, consensus $1.64 KEYS Keysight Technologies $166.33 / -0.99 (-0.59%) 03/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/17/22 Keysight Technologies - KEYS

Events

Earnings calls, analyst events, roadshows and more

XYF
Today at 07:00

X Financial - XYF Conference Calls
AXSM
Today at 08:00

Axsome Therapeutics - AXSM Conference Calls
KPLT
Today at 08:00

Katapult - KPLT Conference Calls
KLTR
Today at 08:00

Kaltura - KLTR Conference Calls
SDC
Today at 08:00

SmileDirectClub - SDC Conference Calls
AVDL
Today at 08:00

Avadel Pharmaceuticals - AVDL Conference Calls
REYN
Today at 08:00

Reynolds Consumer Products - REYN Conference Calls
ACM
Today at 08:00

Aecom - ACM Conference Calls
CIFR
Today at 08:00

Cipher Mining - CIFR Conference Calls
CBT
Today at 08:00

Cabot - CBT Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord $0.59 MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities $1.45-1.55
Tues	CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler $35.00 6M Shares KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies $241.19 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity $5.00 3M Shares PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler $28.44 8M Shares SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital $16.01 8.5M Shares
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Americold Realty Trust price target raised to $33 from $29 at Baird

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access